Table 3.
Treatments administered for castration-resistant prostate cancer
| Overall (n = 299) |
Clinical trial | |||
|---|---|---|---|---|
| Participants (n = 65) |
Non-participants (n = 234) |
p | ||
| Docetaxel | ||||
| N | 242 (80.9%) | 41 (63.1%) | 201 (85.9%) | 0.001 |
| No. cycles | 4.0 (2.0–9.0) | 7.0 (4.0–12.5) | 4.0 (2.0–9.0) | 0.003 |
| ARAT agent use | ||||
| Pre-chemotherapy | 0.502 | |||
| Abiraterone | 10 (3.3%) | 2 (3.1%) | 8 (3.4%) | |
| Enzalutamide | 15 (5.0%) | 4 (6.2%) | 11 (4.7%) | |
| Post-chemotherapy | < 0.001 | |||
| Abiraterone | 23 (7.7%) | 13 (20.0%) | 10 (4.3%) | |
| Enzalutamide | 108 (36.1%) | 9 (13.8%) | 99 (42.3%) | |
| Cabazitaxel | 1 (0.3%) | 0 (0.0%) | 1 (0.4%) | 1.000 |
| Radium-223 | 5 (1.7%) | 3 (4.6%) | 2 (0.9%) | 0.070 |
Abbreviations: ARAT androgen receptor axis-targeted